ArticleScientific reports2026
In vitro investigation of osteogenic differentiation and bone regeneration potential of magnesium oxide nanoparticles incorporated into bacterial cellulose/silk fibroin scaffolds.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study developed porous scaffolds composed of silk fibroin (SF), bacterial cellulose (BC), and magnesium oxide nanoparticles (MgONPs) via freeze-drying to investigate their potential for bone tissue engineering (BTE). The scaffolds were characterized using scanning electron microscopy (SEM) and Fourier transform infrared spectroscopy (FTIR), and assessed for porosity, compressive strength, swelling ratio, and degradation rate. Biological evaluations included cell attachment, proliferation, and osteogenic differentiation of human adipose-derived stem cells (hASCs). Results indicated that the incorporation of MgONPs influenced scaffold properties, leading to a decrease in pore size and swelling capacity (p = 0.001). MTT assay confirmed high cell viability across all scaffolds, with BC/SF/MgONPs demonstrating enhanced biocompatibility after 72 h (p = 0.016 vs. SF). Furthermore, BC/SF and BC/SF/MgONPs scaffolds exhibited minimal hemolysis, suggesting improved hemocompatibility. Alkaline phosphatase (ALP) activity and alizarin red S staining analyses revealed significantly increased osteogenic potential for BC/SF/MgONPs scaffolds compared to SF scaffolds (p = 0.027 and p = 0.002, respectively vs. SF). Consistent with these findings, BC/SF/MgONPs scaffolds led to a significant increase in the expression of early and late osteogenic markers, namely RUNX2 (p = 0.001), ALP (p = 0.002), and BGLAP (p = 0.016). These findings demonstrate that BC/SF/MgONPs scaffolds may represent an effective system for promoting the osteogenic differentiation of hASCs and hold promise for BTE applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.